{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T00:55:17Z","timestamp":1794099317114,"version":"4.8.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>New approaches are needed to lower blood pressure (BP) given persistently low control rates. QUARTET USA sought to evaluate the effect of four-drug, quarter-dose BP lowering combination in patients with hypertension. QUARTET USA was a randomized (1:1), double-blinded trial conducted in federally qualified health centers among adults with hypertension. Participants received either a quadpill of candesartan 2\u2009mg, amlodipine 1.25\u2009mg, indapamide 0.625\u2009mg, and bisoprolol 2.5\u2009mg or candesartan 8\u2009mg for 12 weeks. If BP was &gt;130\/&gt;80\u2009mm Hg at 6 weeks in either arm, then participants received open label add-on amlodipine 5\u2009mg. The primary outcome was mean change in systolic blood pressure (SBP) at 12 weeks, controlling for baseline BP. Secondary outcomes included mean change in diastolic blood pressure (DBP), and safety included serious adverse events, relevant adverse drug effects, and electrolyte abnormalities. Among 62 participants randomized between August 2019-May 2022 (<jats:italic>n<\/jats:italic>\u2009=\u200932 intervention, <jats:italic>n<\/jats:italic>\u2009=\u200930 control), mean (SD) age was 52 (11.5) years, 45% were female, 73% identified as Hispanic, and 18% identified as Black. Baseline mean (SD) SBP was 138.1 (11.2) mmHg, and baseline mean (SD) DBP was 84.3 (10.5) mmHg. In a modified intention-to-treat analysis, there was no significant difference in SBP (\u22124.8\u2009mm Hg [95% CI: \u221210.8, 1.3, <jats:italic>p<\/jats:italic>\u2009=\u20090.123] and a \u22124.9\u2009mmHg (95% CI: \u22128.6, \u22121.3, <jats:italic>p<\/jats:italic>\u2009=\u20090.009) greater mean DBP change in the intervention arm compared with the control arm at 12 weeks. Adverse events did not differ significantly between arms. The quadpill had a similar SBP and greater DBP lowering effect compared with candesartan 8\u2009mg. Trial registration number: NCT03640312.<\/jats:p>","DOI":"10.1038\/s41440-024-01658-y","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T03:10:17Z","timestamp":1712545817000},"page":"1668-1677","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Efficacy and safety of a four-drug, quarter-dose treatment for hypertension: the QUARTET USA randomized trial"],"prefix":"10.1038","volume":"47","author":[{"given":"Mark D.","family":"Huffman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail S.","family":"Baldridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Lazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiba","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jairo","family":"Mejia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fallon M.","family":"Flowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Quintana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alema","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namratha R.","family":"Kandula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald M.","family":"Lloyd-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Persell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadiya S.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Paparello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aashima","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"My H.","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara K.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jody D.","family":"Ciolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,8]]},"reference":[{"key":"1658_CR1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","volume":"398","author":"B Zhou","year":"2021","unstructured":"NCD-Risk Factor Collaborators, Zhou B, Carrillo-Larco RM, Danaei G, Riley LM, Paciorek CJ, et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398:957\u201380.","journal-title":"Lancet"},{"key":"1658_CR2","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1161\/HYPERTENSIONAHA.122.19222","volume":"79","author":"P Muntner","year":"2022","unstructured":"Muntner P, Miles MA, Jaeger BC, Hannon Iii L, Hardy ST, Ostchega Y, et al. Blood pressure control among US adults, 2009 to 2012 through 2017 to 2020. Hypertension. 2022;79:1971\u201380.","journal-title":"Hypertension"},{"key":"1658_CR3","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"PK Whelton","year":"2017","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison-Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;71:e127\u2013e248.","journal-title":"J Am Coll Cardiol"},{"key":"1658_CR4","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021\u2013104.","journal-title":"Eur Heart J"},{"key":"1658_CR5","unstructured":"World Health Organization. Guideline for the pharmacological treatment of hypertension in adults. WHO Report: Geneva; 2021."},{"key":"1658_CR6","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","volume":"147","author":"CW Tsao","year":"2023","unstructured":"Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. Heart disease and stroke statistics\u20142023 update: a report from the American Heart Association. Circulation 2023;147:e93\u2013e621.","journal-title":"Circulation"},{"key":"1658_CR7","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(19)31293-0","volume":"394","author":"CK Chow","year":"2019","unstructured":"Chow CK, Gupta R. Blood pressure control: a challenge to global health systems. Lancet. 2019;394:613\u20135.","journal-title":"Lancet"},{"key":"1658_CR8","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1161\/HYPERTENSIONAHA.119.14360","volume":"75","author":"CG Derington","year":"2020","unstructured":"Derington CG, King JB, Herrick JS, Shimbo D, Kronish IM, Saseen JJ, et al. Trends in antihypertensive medication monotherapy and combination use among US adults, National Health and Nutrition Examination Survey 2005\u20132016. Hypertension. 2020;75:973\u201381.","journal-title":"Hypertension"},{"key":"1658_CR9","first-page":"238146831665601","volume":"1","author":"A Olomu","year":"2016","unstructured":"Olomu A, Khan NNS, Todem D, Huang Q, Bottu S, Qadri S, et al. Blood pressure control in hypertensive patients in federally qualified health centers. Mdm Policy Pr. 2016;1:2381468316656010.","journal-title":"Mdm Policy Pr"},{"key":"1658_CR10","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1136\/bmj.326.7404.1427","volume":"326","author":"MR Law","year":"2003","unstructured":"Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326:1427\u201331.","journal-title":"BMJ"},{"key":"1658_CR11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1161\/HYPERTENSIONAHA.117.09202","volume":"70","author":"A Bennett","year":"2017","unstructured":"Bennett A, Chow CK, Chou M, Dehbi H-M, Webster R, Salam A, et al. Efficacy and safety of quarter-dose blood pressure-lowering agents: a systematic review and meta-analysis of randomized controlled trials. Hypertension. 2017;70:85\u201393.","journal-title":"Hypertension"},{"key":"1658_CR12","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1111\/jch.14009","volume":"22","author":"A Salam","year":"2020","unstructured":"Salam A, Huffman MD, Kanukula R, Prasad EH, Sharma A, Heller DJ, et al. Two\u2010drug fixed\u2010dose combinations of blood pressure\u2010lowering drugs as WHO essential medicines: an overview of efficacy, safety, and cost. J Clin Hypertens. 2020;22:1769\u201379.","journal-title":"J Clin Hypertens"},{"key":"1658_CR13","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1097\/HJH.0000000000002089","volume":"37","author":"A Salam","year":"2019","unstructured":"Salam A, Atkins ER, Hsu B, Webster R, Patel A, Rodgers A. Efficacy and safety of triple versus dual combination blood pressure-lowering drug therapy. J Hypertens. 2019;37:1567\u201373.","journal-title":"J Hypertens"},{"key":"1658_CR14","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1161\/HYPERTENSIONAHA.120.15781","volume":"77","author":"G Parati","year":"2021","unstructured":"Parati G, Kjeldsen S, Coca A, Cushman WC, Wang J. Adherence to single-pill versus free-equivalent combination therapy in hypertension. Hypertension. 2021;77:692\u2013705.","journal-title":"Hypertension"},{"key":"1658_CR15","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/S0140-6736(21)01922-X","volume":"398","author":"CK Chow","year":"2021","unstructured":"Chow CK, Atkins ER, Hillis GS, Nelson MR, Reid CM, Schlaich MP, et al. Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial. Lancet. 2021;398:1043\u201352.","journal-title":"Lancet"},{"key":"1658_CR16","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1370\/afm.708","volume":"5","author":"IU Park","year":"2007","unstructured":"Park IU, Taylor AL. Race and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: a systematic review. Ann Fam Med. 2007;5:444\u2013452.","journal-title":"Ann Fam Med"},{"key":"1658_CR17","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ahj.2022.09.004","volume":"254","author":"AS Baldridge","year":"2022","unstructured":"Baldridge AS, Huffman MD, Lazar D, Abbas H, Flowers FM, Quintana A, et al. Efficacy and safety of a quadruple ultra-low-dose treatment for hypertension (QUARTET USA): rationale and design for a randomized controlled trial. Am Heart J. 2022;254:183\u201393.","journal-title":"Am Heart J"},{"key":"1658_CR18","doi-asserted-by":"publisher","first-page":"e032236","DOI":"10.1161\/JAHA.123.032236","volume":"13","author":"OA Sanuade","year":"2024","unstructured":"Sanuade OA, Jacobson TA, Quintana A, Flowers FM, Abbasi H, Vu MH, et al. Process evaluation of a double blind randomized controlled trial to assess the efficacy and safety of a quadruple ultra-low-dose treatment for hypertension within a federally qualified health center network (QUARTET USA). J Am Heart Assoc. 2024;13:e032236.","journal-title":"J Am Heart Assoc"},{"key":"1658_CR19","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1370\/afm.405","volume":"3","author":"BD Weiss","year":"2005","unstructured":"Weiss BD. Quick assessment of literacy in primary care: the Newest Vital Sign. Ann Fam Med. 2005;3:514\u201322.","journal-title":"Ann Fam Med"},{"key":"1658_CR20","unstructured":"Medical Dictionary for Regulatory Activities. International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH). Available from: https:\/\/www.ich.org\/page\/meddra. Accessed January 9, 2024."},{"key":"1658_CR21","doi-asserted-by":"publisher","first-page":"100219","DOI":"10.1016\/j.lana.2022.100219","volume":"9","author":"NRC Campbell","year":"2022","unstructured":"Campbell NRC, Burnens MP, Whelton PK, Angell SY, Jaffe MG, Cohn J, et al. 2021 World Health Organization guideline on pharmacological treatment of hypertension: policy implications for the region of the Americas. Lancet Regional Heal - Am. 2022;9:100219.","journal-title":"Lancet Regional Heal - Am"},{"key":"1658_CR22","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","volume":"373","author":"JT Wright Jr","year":"2015","unstructured":"Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103\u201316.","journal-title":"N Engl J Med"},{"key":"1658_CR23","unstructured":"National Association of Community Health Centers. America\u2019s health centers fact sheet, August 2022. Available from: https:\/\/www.nachc.org\/wp-content\/uploads\/2022\/08\/Americas-Health-Centers-2022_final.pdf. Accessed January 9, 2024."},{"key":"1658_CR24","doi-asserted-by":"publisher","first-page":"e018512","DOI":"10.1161\/JAHA.120.018512","volume":"9","author":"AR Zheutlin","year":"2020","unstructured":"Zheutlin AR, Caldwell D, Anstey DE, Conroy MB, Ogedegbe O, Bress AP. Trends in hypertension clinical trials focused on interventions specific for Black adults: an analysis of clinicaltrials.gov. J Am Hear Assoc. 2020;9:e018512.","journal-title":"J Am Hear Assoc"},{"key":"1658_CR25","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/ajh\/hpu233","volume":"28","author":"M Mueller","year":"2014","unstructured":"Mueller M, Purnell TS, Mensah GA, Cooper LA. Reducing racial and ethnic disparities in hypertension prevention and control: what will it take to translate research into practice and policy? Am J Hypertens. 2014;28:699\u2013716.","journal-title":"Am J Hypertens"},{"key":"1658_CR26","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1001\/jamacardio.2020.2739","volume":"5","author":"Wang","year":"2020","unstructured":"Wang, Salam N, Webster A, Silva R, de A, Guggilla R, Stepien S, et al. Association of low-dose triple combination therapy with therapeutic inertia and prescribing patterns in patients with hypertension: a secondary analysis of the TRIUMPH trial. JAMA Cardiol. 2020;5:1219\u201326.","journal-title":"JAMA Cardiol"},{"key":"1658_CR27","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1177\/1060028015570468","volume":"49","author":"T-L Laba","year":"2015","unstructured":"Laba T-L, Howard K, Rose J, Peiris D, Redfern J, Usherwood T, et al. Patient preferences for a polypill for the prevention of cardiovascular diseases. Ann Pharmacother. 2015;49:528\u201339.","journal-title":"Ann Pharmacother"},{"key":"1658_CR28","doi-asserted-by":"publisher","first-page":"e008018","DOI":"10.1136\/bmjopen-2015-008018","volume":"5","author":"F Wood","year":"2015","unstructured":"Wood F, Salam A, Singh K, Day S, Jan S, Prabhakaran D, et al. Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease. BMJ Open. 2015;5:e008018.","journal-title":"BMJ Open"},{"key":"1658_CR29","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ahj.2020.09.017","volume":"231","author":"CK Chow","year":"2021","unstructured":"Chow CK, Atkins ER, Billot L, Chalmers J, Hillis GS, Hay P, et al. Ultra-low-dose quadruple combination blood pressure lowering therapy in patients with hypertension: The QUARTET randomized controlled trial protocol. Am Heart J. 2021;231:56\u201367.","journal-title":"Am Heart J"},{"key":"1658_CR30","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/S0140-6736(17)30260-X","volume":"389","author":"CK Chow","year":"2017","unstructured":"Chow CK, Thakkar J, Bennett A, Hillis G, Burke M, Usherwood T, et al. Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review. Lancet. 2017;389:1035\u201342.","journal-title":"Lancet"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-01658-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-01658-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-01658-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T23:09:51Z","timestamp":1717542591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-01658-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,8]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1658"],"URL":"https:\/\/doi.org\/10.1038\/s41440-024-01658-y","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,8]]},"assertion":[{"value":"19 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MDH has received travel support from the American Heart Association and World Heart Federation and consulting fees from PwC Switzerland. MDH has an appointment at The George Institute for Global Health, which has a patent, license, and has received investment funding with intent to commercialize fixed-dose combination therapy through its social enterprise business, George Medicines. MDH has pending patents for heart failure polypills. CKC has a patent for quarter-dose, quadruple drug combination therapy for blood pressure lowering. SDP receives unrelated research support from Omron Healthcare Co. Ltd. and honoraria for speaking from Omron Healthcare Co. and the National Committee for Quality Assurance. The remaining authors have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}